.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Pancreatic cancer management is evolving rapidly through biotechnology. A promising frontier involves siRNA pancreatic cancer therapy, which uses small ribonucleotides to silence disease-causing genes. Consequently, these molecules can target specific DNA sequences and reduce their expression levels. Since changes in gene expression drive pancreatic cancer, this mechanism provides a powerful tool for intervention.
Silencing critical genes like K-Ras and GJB4 effectively blocks tumor development. Furthermore, siRNAs can improve the efficacy of standard chemotherapeutic drugs. Drugs such as gemcitabine and paclitaxel often face resistance. However, researchers have found that siRNA can reduce drug-resistance-related genes. Therefore, the combination of chemical agents and immunological agents may significantly improve patient survival. Additionally, innovative delivery systems are essential to protect siRNAs from degradation in the bloodstream.
In addition to chemotherapy, siRNAs enhance the effectiveness of immunotherapy. They can modulate the tumor microenvironment to allow immune cells to attack cancer more effectively. Moreover, recent clinical trials indicate that extended-release implants delivering anti-KRAS siRNAs show promising survival trends. These advancements suggest a shift toward more personalized and potent cancer care strategies. Physicians should monitor these developments closely as they transition into clinical practice.
siRNA molecules target and silence genes responsible for drug resistance. This makes cancer cells more susceptible to chemotherapeutic agents like doxorubicin and gemcitabine, thereby increasing treatment efficacy.
Key targets include the K-Ras, GJB4, and SIX4 genes. Silencing these specific genetic sequences can block or even reverse the progression of pancreatic cancer cells.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or professional services. Always seek the advice of your physician or other qualified health provider regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
siRNA therapy combined with chemotherapy offers a novel approach to silence genes like K-Ras, potentially improving pancreatic cancer treatment outcomes....
4 months ago
Explore vital recurrent stroke predictors in lacunar stroke patients managed with intensive blood pressure lowering. This analysis examines trial findings from SPS3 to uncover residual vascular risks, metabolic factors, and targeted secondary prevention strategies for high-risk neurological patients.
Today
A comprehensive scoping review synthesises evidence linking prenatal maternal mental health to long-term offspring neurodevelopment, evaluating neuroendocrine, inflammatory, and epigenetic pathways while highlighting clinical screening and future research priorities.
Today
The Directorate General of Health Services directs Indian states to halt the hazardous reuse and reprocessing of single-use medical devices. Discover regulatory implications under the Drugs and Cosmetics Act, critical infection risks, legal liabilities, and operational changes required across clinical specialties.
Today
Mitochondria-targeted nanoparticles self-assembled from EGCG and L-glutamic acid effectively restore mitochondrial homeostasis, suppress synovial inflammation, and attenuate chondrocyte senescence in osteoarthritis, offering a promising disease-modifying nanotherapy.
Today
India is advancing preventive healthcare by integrating genomics, artificial intelligence, and quantum technologies. With the SANGAM programme sequencing one million Indian genomes, clinicians can unlock personalized therapies, detect cardiometabolic risks early, and curb the burden of diabetes and heart disease.
Today
